Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

Washington,	D.C.	20549	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response	0.5							

					01	Occi	00(11)	31 1110	111100	incinc c	2011	ірапу Асі	01 134	+0							
1. Name and Address of Reporting Person* SIDRANSKY DAVID					2. Issuer Name and Ticker or Trading Symbol Ayala Pharmaceuticals, Inc. [AYLA]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
SIDRANSK I DAVID													-"		X Direct	or		10% Ov	vner		
(Last) OPPENI	(F HEIMER 4	irst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/10/2021								Officer below)	(give title		Other (s below)	specify			
						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Ir	6. Individual or Joint/Group Filing (Check Applicable						
(Street)								9		(.,,,	,	Line	Line) X Form filed by One Reporting Person							
REHOV	OT L	3	7647412											_	,		n One Repo				
(City)	(S	tate)	(Zip)			Person									1						
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
4 711									÷											7. Notono	
1. Title of Security (Instr. 3) 2. Trans Date (Month/					action 2A. Deemed Execution Date, if any (Month/Day/Year)			, Tr	3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)					Securities Beneficially Owned Follo		Form (D) o	n: Direct r Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership			
							C	ode V	,	Amount (A) or (D)		Price	Reporte Transac (Instr. 3	saction(s) r. 3 and 4)			(Instr. 4)				
		•	Table II -									sed of, onvertil				Owned					
1. Title of Derivative Security (Instr. 3)	1. Title of 2. 3. Transaction Date Security or Exercise (Month/Day/Year) if any			saction of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		s Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securitie: Beneficia Owned Following Reported Transacti (Instr. 4)	e s ully	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership ct (Instr. 4)				
					Code	v	(A)	(D)	Date Exer	cisable		xpiration ate	Title		Amount or Number of Shares						
Stock Option (Right to Buy)	\$10.35	06/10/2021			A		12,500			(1)	0	6/09/2031	Com		12,500	\$0.00	12,50	00	D		

Explanation of Responses:

1. This option vests and becomes exercisable on the earlier of (i) June 10, 2022 or (ii) one day prior to the Company's 2022 annual meeting of shareholders, subject to the Reporting Person's continued service with the Issuer through such vesting date.

Remarks:

/s/ Roni Mamluk, Ph.D.,

Attorney-in-Fact for David <u>Sidransky</u>

** Signature of Reporting Person Date

06/14/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.